The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Official Title: A Phase IB Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Study ID: NCT02670044
Brief Summary: The primary objective for this study is to assess the safety and tolerability as well as preliminary efficacy of venetoclax in combination with cobimetinib, and venetoclax in combination with idasanutlin in patients with relapsed or refractory acute myeloid leukemia (R/R) AML who are not eligible for cytotoxic therapy.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
USC Norris Cancer Center, Los Angeles, California, United States
UC Davis; Comprehensive Cancer Center, Sacramento, California, United States
Univ of Calif, San Francisco, San Francisco, California, United States
University of Colorado, Aurora, Colorado, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Weill Cornell Medical College, New York, New York, United States
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
MD Anderson Cancer Center, Houston, Texas, United States
University of Alberta Hospital, Edmonton, Alberta, Canada
Princess Margaret Cancer Center, Toronto, Ontario, Canada
Jewish General Hospital, Montreal, Quebec, Canada
Hopital Avicenne, Paris, Bobigny, , France
Institut Paoli Calmettes, Marseille, , France
CHU de Bordeaux, Pessac, , France
University of Bologna, Bologna, Emilia-Romagna, Italy
Presidio san salvatore muraglia, Pesaro, Emilia-Romagna, Italy
Universita di Roma, Roma, Emilia-Romagna, Italy
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR